Cabozantinib (Cabometyx, 6) – Cabometyx®

Adults with locally advanced or metastatic differentiated thyroid carcinoma (DTC) who are refractory to radioiodine (RAI) or for whom RAI is not an option, and who have shown disease progression during or after previous systemic therapy

• The additional benefit is not proven.
• For the treatment of adults with locally advanced or metastatic differentiated thyroid carcinoma (DTC) who are refractory to radioiodine (RAI) or are not eligible for it, and in whom disease progression has occurred during or after previous systemic therapy, the pharmaceutical manufacturer has not submitted any data for the assessment of additional benefit.
• Summary of the assessment
  • The pharmaceutical manufacturer has not submitted any data that would enable an assessment of additional benefit. Additional benefit is therefore not proven.

Courtesy translation only, please refer to the German original.